These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 26113208)

  • 1. Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study.
    Langone A; Steinberg SM; Gedaly R; Chan LK; Shah T; Sethi KD; Nigro V; Morgan JC;
    Clin Transplant; 2015 Sep; 29(9):796-805. PubMed ID: 26113208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Switching From Immediate- or Prolonged-Release to Once-Daily Extended-Release Tacrolimus (LCPT) on Tremor in Stable Kidney Transplant Recipients: The Observational ELIT Study.
    Giral M; Grimbert P; Morin B; Bouvier N; Buchler M; Dantal J; Garrigue V; Bertrand D; Kamar N; Malvezzi P; Moreau K; Athea Y; Le Meur Y
    Transpl Int; 2024; 37():11571. PubMed ID: 38694490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients.
    Gaber AO; Alloway RR; Bodziak K; Kaplan B; Bunnapradist S
    Transplantation; 2013 Jul; 96(2):191-7. PubMed ID: 23715050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients.
    Alloway RR; Eckhoff DE; Washburn WK; Teperman LW
    Liver Transpl; 2014 May; 20(5):564-75. PubMed ID: 24493215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic Study of Conversion Between 2 Formulations of Once-daily Extended-release Tacrolimus in Stable Lung Transplant Patients.
    Sintes H; Sáez-Giménez B; Berastegui C; López-Meseguer M; Monforte V; Bravo C; Vima J; Gómez-Ollés S; Roman A
    Transplantation; 2018 Oct; 102(10):e439-e446. PubMed ID: 29965950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion From Immediate-Release to Prolonged-Release Tacrolimus in Kidney Transplant Patients With Tremor: A Case Series Study.
    Kamińska D; Hożejowski R; Chamienia A; Dębska-Ślizień A; Idasiak-Piechocka I; Oko A; Baranowicz-Gąszczyk I; Załuska W; Mazanowska O; Krajewska M
    Transplant Proc; 2024 May; 56(4):776-780. PubMed ID: 38453593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study.
    Kamar N; Cassuto E; Piotti G; Govoni M; Ciurlia G; Geraci S; Poli G; Nicolini G; Mariat C; Essig M; Malvezzi P; Le Meur Y; Garrigue V; Del Bello A; Rostaing L
    Adv Ther; 2019 Feb; 36(2):462-477. PubMed ID: 30552587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
    Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K;
    Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LCPT once-daily extended-release tacrolimus tablets versus twice-daily capsules: a pooled analysis of two phase 3 trials in important de novo and stable kidney transplant recipient subgroups.
    Bunnapradist S; Rostaing L; Alloway RR; West-Thielke P; Denny J; Mulgaonkar S; Budde K
    Transpl Int; 2016 May; 29(5):603-11. PubMed ID: 26953629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant.
    DuBay DA; Teperman L; Ueda K; Silverman A; Chapman W; Alsina AE; Tyler C; Stevens DR
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):995-1008. PubMed ID: 30667591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial.
    Budde K; Bunnapradist S; Grinyo JM; Ciechanowski K; Denny JE; Silva HT; Rostaing L;
    Am J Transplant; 2014 Dec; 14(12):2796-806. PubMed ID: 25278376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial.
    Suwelack B; Bunnapradist S; Meier-Kriesche U; Stevens DR; Procaccianti C; Morganti R; Budde K
    Ann Transplant; 2020 Jul; 25():e923278. PubMed ID: 32719307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Envarsus XR® pharmacokinetics in adolescents post-kidney transplantation - A pilot study.
    ElChaki R; Ettenger R; Lee S; Chen L; Gales B; Srivastava R; Pearl M
    Pediatr Transplant; 2023 May; 27(3):e14480. PubMed ID: 36732080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial.
    Faravardeh A; Akkina S; Villicana R; Guerra G; Moten MA; Meier-Kriesche U; Stevens DR; Patel SJ; Bunnapradist S
    Ann Transplant; 2021 Apr; 26():e929535. PubMed ID: 33859155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations.
    Grinyó JM; Petruzzelli S
    Expert Rev Clin Immunol; 2014 Dec; 10(12):1567-79. PubMed ID: 25407098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients.
    Nakamura Y; Hama K; Katayama H; Soga A; Toraishi T; Yokoyama T; Kihara Y; Jojima Y; Konno O; Iwamoto H; Takeuchi H; Hirano T; Shimazu M
    Transplant Proc; 2012 Jan; 44(1):124-7. PubMed ID: 22310595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of the conversion to MeltDose
    Sánchez Fructuoso A; Ruiz JC; Franco A; Diekmann F; Redondo D; Calviño J; Serra N; Aladrén MJ; Cigarrán S; Manonelles A; Ramos A; Gómez G; González Posada JM; Andrés A; Beneyto I; Muñiz AL; Perelló M; Lauzurica R
    Clin Transplant; 2020 Jan; 34(1):e13767. PubMed ID: 31815310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial.
    Bunnapradist S; Ciechanowski K; West-Thielke P; Mulgaonkar S; Rostaing L; Vasudev B; Budde K;
    Am J Transplant; 2013 Mar; 13(3):760-9. PubMed ID: 23279614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation.
    Glander P; Waiser J; Kasbohm S; Friedersdorff F; Peters R; Rudolph B; Wu K; Budde K; Liefeldt L
    Clin Transplant; 2018 Aug; 32(8):e13311. PubMed ID: 29888809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen.
    Alloway R; Steinberg S; Khalil K; Gourishankar S; Miller J; Norman D; Hariharan S; Pirsch J; Matas A; Zaltzman J; Wisemandle K; Fitzsimmons W; First MR
    Transplant Proc; 2005 Mar; 37(2):867-70. PubMed ID: 15848559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.